Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Kanazawa, Japan;
Department of Clinical Pharmacy and Healthcare Sciences, Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University, Kanazawa, Japan.
In Vivo. 2021 Jan-Feb;35(1):401-410. doi: 10.21873/invivo.12271.
BACKGROUND/AIM: Reportedly, sarcopenia and nutritional status are associated with prognosis in cancer patients. However, data regarding the relationship of these factors with advanced thyroid cancer patients receiving molecular targeted therapy remains scarce. Therefore, we investigated the relationship between nutritional assessment, as well as sarcopenia, and prognosis in patients with advanced thyroid cancer undergoing molecular targeted therapy.
In this retrospective study, sarcopenia and several markers of nutritional status were assessed in advanced thyroid cancer patients at the Kanazawa University Hospital, before the introduction of molecular targeted therapy.
Advanced thyroid cancer patients with sarcopenia presented a worse prognosis than those without sarcopenia. Additionally, sarcopenia strongly correlated with several markers of nutritional status, such as albumin, prognostic nutrition index, and Glasgow prognostic score.
Sarcopenia could be a prognostic factor in patients with advanced thyroid cancer receiving molecular targeted therapy.
背景/目的：据报道，肌肉减少症和营养状况与癌症患者的预后相关。然而，关于这些因素与接受分子靶向治疗的晚期甲状腺癌患者之间关系的数据仍然很少。因此，我们研究了在接受分子靶向治疗的晚期甲状腺癌患者中，营养评估以及肌肉减少症与预后之间的关系。
在这项回顾性研究中，在金泽大学医院引入分子靶向治疗之前，评估了晚期甲状腺癌患者的肌肉减少症和几种营养状况标志物。
患有肌肉减少症的晚期甲状腺癌患者的预后比没有肌肉减少症的患者差。此外，肌肉减少症与几种营养状况标志物（如白蛋白、预后营养指数和格拉斯哥预后评分）密切相关。
肌肉减少症可能是接受分子靶向治疗的晚期甲状腺癌患者的预后因素。
